By simultaneously downregulating the VEGFR‐2 and ANG‐2 levels, LYTAC Plus hydrogel designed for alleviating neovascular age‐related macular degeneration (n‐AMD) shows a better therapeutic efficacy compared to the conventional approach in the mouse model, indicating its potential as a versatile platform for disease treatments. This evidence concerns the gene ANGPT2 and age-related macular degeneration.